Skip to main content
main-content

ASCO GU 2020

2020 Genitourinary Cancers Symposium coverage

Breaking news and expert interviews from the meeting in San Francisco (February 13–15, 2020).

16-02-2020 | ASCO GU 2020 | Conference coverage | Video

Expert highlights from ASCO GU 2020

Axel Merseburger takes us through the studies that caught his attention at ASCO GU 2020, including the NIMBUS trial and first-in-human study of the HIF-2α inhibitor MK-6482 (3:24).

Expert discussion

25-02-2020 | Renal cell carcinoma | Conference coverage | Video

Treatment options for advanced RCC: Updates from ASCO GU 2020

Axel Merseburger and Laurence Albigès discuss the treatment options for patients with advanced renal cell carcinoma and highlight some of the novel data presented at the 2020 Genitourinary Cancers Symposium that may affect practice in the future.

This independent video was supported by an educational grant from Pfizer and Merck KGaA.

25-02-2020 | Renal cell carcinoma | Conference coverage | Video

Metastatic RCC updates from ASCO GU 2020

Bernard Escudier and Viktor Grünwald take us through the metastatic renal cell carcinoma studies that caught their attention at the 2020 Genitourinary Cancers Symposium, including long-term data from the CheckMate 214 trial and studies of novel agents such as the HIF-2α inhibitor MK-6482 and sitravatinib.

This independent video was supported by an educational grant from Pfizer and Merck KGaA.

mPC trials and localized prostate cancer RT

17-02-2020 | ASCO GU 2020 | Conference coverage | Video

Researcher comment: The COSMIC-021 mCRPC cohort

Neeraj Agarwal outlines the findings of the metastatic castration-resistant prostate cancer cohort of the COSMIC-021 trial of cabozantinib plus atezolizumab (3:21).

Read the accompanying news story

15-02-2020 | ASCO GU 2020 | Conference coverage | Video

Expert comment: The CARD, TITAN, and STOMP trials

ASCO expert Robert Dreicer shares his views on the updates from the CARD, TITAN, and STOMP prostate cancer trials presented at ASCO GU 2020 (3:07).

Read more about the STOMP trial and the CARD trial

14-02-2020 | ASCO GU 2020 | Conference coverage | News

Long-term CHHiP data further support hypofractionated radiotherapy for prostate cancer

The 8-year results from the phase 3 CHHiP trial have confirmed the noninferiority of moderately hypofractionated radiotherapy delivering 60 Gy in 20 fractions to the conventional regimen for the control of localized prostate cancer.

26-02-2020 | ASCO GU 2020 | Conference coverage | News

Pembrolizumab–enzalutamide combination has ‘modest activity’ in mCRPC

The addition of pembrolizumab to enzalutamide has “modest activity” against metastatic castration-resistant prostate cancer that has become resistant to enzalutamide, say the KEYNOTE-199 researchers.

25-02-2020 | ASCO GU 2020 | Conference coverage | News

STAMPEDE: Better QoL with abiraterone than docetaxel in prostate cancer

Abiraterone is associated with improved quality of life relative to docetaxel in men with hormone-naïve prostate cancer, shows an analysis of contemporaneously randomized participants of the STAMPEDE trial.

Immunotherapy in RCC: Combinations with surgery and RT, biomarkers

16-02-2020 | ASCO GU 2020 | Conference coverage | Video

Researcher comment: Cytoreductive nephrectomy in the ICI era

Ziad Bakouny presents data on cytoreductive nephrectomy outcomes in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors that suggest there may yet be a role for the procedure in certain patients (4:43).

This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

Read the accompanying news story

15-02-2020 | ASCO GU 2020 | Conference coverage | Video

Researcher comment: The RADVAX RCC study

Hans Hammers discusses the RADVAX RCC trial combining dual checkpoint blockade and stereotactic body radiotherapy for the treatment of metastatic renal cell carcinoma, and also comments on the similar NIVES study (2:16).

Read the accompanying news story

This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

15-02-2020 | ASCO GU 2020 | Conference coverage | Video

Researcher comment: Molecular correlates of nivolumab outcomes in RCC

Yann-Alexandre Vano describes a translational analysis of the NIVOREN GETUG-AFU 26 trial to identify biomarkers associated with outcomes in nivolumab-treated patients with metastatic clear cell renal cell carcinoma (3:29).

This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

New agents in RCC: Sitravatinib and MK-6482

16-02-2020 | ASCO GU 2020 | Conference coverage | Video

Expert comment: Novel agents in advanced RCC

Daniel Geynisman discusses the potential for the novel tyrosine kinase inhibitor sitravatinib and the HIF-2α inhibitor MK-6482 to change the treatment paradigm in advanced clear-cell renal cell carcinoma (4:47).

16-02-2020 | ASCO GU 2020 | Conference coverage | Video

Researcher comment: Sitravatinib plus nivolumab in advanced RCC

Pavlos Msaouel reports on the efficacy and toxicity of combined treatment with the novel tyrosine kinase inhibitor sitravatinib and nivolumab in people with advanced renal cell carcinoma (4:53).

15-02-2020 | ASCO GU 2020 | Conference coverage | Video

Researcher comment: HIF-2α inhibition in RCC

Toni Choueiri reports on the advanced renal cell carcinoma cohort of the phase 1/2 trial of MK-6482, a first-in-class inhibitor of hypoxia-inducible factor (HIF)-2α (2:36).

Neoadjuvant immunotherapy/chemotherapy in MIBC: BLASST-1 and NEO-BLADE

15-02-2020 | ASCO GU 2020 | Conference coverage | Video

Researcher comment: The BLASST-1 trial

Shilpa Gupta gives the top-line results of their trial investigating the addition of nivolumab to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. She also discusses the neoadjuvant NEO-BLADE study presented at the conference and speculates on the reasons for the differing results (3:16).

New agents in bladder cancer: PARP inhibitors, gene therapy, and EV-103

17-02-2020 | ASCO GU 2020 | Conference coverage | Video

Researcher comment: The ATLAS trial

Petros Grivas explains why the story of PARP inhibitors in advanced urothelial carcinoma is not quite finished yet despite the negative results of the ATLAS trial of rucaparib in this setting (4:45).

Read the accompanying news story

15-02-2020 | ASCO GU 2020 | Conference coverage | News

Novel gene therapy shows promise in non-muscle-invasive bladder cancer

The adenovirus vector-based gene therapy nadofaragene firadenovec elicits durable responses in people with non-muscle-invasive bladder cancer unresponsive to Bacillus Calmette-Guérin, shows a phase 3 trial.

14-02-2020 | ASCO GU 2020 | Conference coverage | Video

Researcher comment: Additional data from the EV-103 trial

Jonathan Rosenberg provides an update on the EV-103 trial of combined enfortumab vedotin plus pembrolizumab for the first-line treatment of cisplatin-ineligible advanced urothelial carcinoma (3:40).

Read the accompanying news story

Other GU tumors

16-02-2020 | ASCO GU 2020 | Conference coverage | News

Chemotherapy de-escalation feasible in metastatic seminoma

SEMITEP trial results reported at the 2020 Genitourinary Cancers Symposium demonstrate the feasibility of treatment de-escalation based on an interim scan in metastatic seminoma patients with good prognosis.

Reference

ASCO GU 2020 key clinical trial overviews

Read concise summaries of the practice-changing clinical trials being presented at ASCO GU 2020. Highlights include the CHHiP, NIVES, NIMBUS, KEYNOTE-199 and RADVAX RCC trials.

Image Credits